• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Healthopioid epidemic

6 More States Just Sued the Oxycontin Maker. How It Could Dramatically Alter the Price of an Opioid Settlement

By
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Bloomberg
Bloomberg
Down Arrow Button Icon
May 16, 2018, 6:00 AM ET

Lawsuits filed against Oxycontin maker Purdue Pharma and other drugmakers by Tennessee and Florida cast more doubt about the viability of settlement talks aimed at addressing the U.S. opioid epidemic.

Tennessee Attorney General Herbert Slatery and Florida’s Pam Bondi on Tuesday accused executives of Purdue and other opioid makers and distributors of fueling a public-health crisis by falsely claiming that the synthetic pain medicine wasn’t addictive. They joined more than 20 other states that have sued companies including Purdue, Johnson & Johnson (JNJ) and McKesson Corp. (MCK) over the products.

It’s a twist for Slatery and Bondi, who have been leading settlement negotiations sponsored by a coalition of attorneys general and who’ve deferred from suing makers and distributors of the drug until now. Four other states — North Carolina, Texas, Nevada and North Dakota — also filed opioid suits Tuesday. They were also part of the talks.

“We are disappointed that after months of good faith negotiations working toward a meaningful resolution to help these states address the opioid crisis, this group of attorneys general have unilaterally decided to pursue a costly and protracted litigation process,” Robert Josephson, a Purdue spokesman, said in an emailed statement.

Separately, hundreds of cities and counties are suing the drugmakers and distributors in cases that have been consolidated before a federal judge in Cleveland. The first trial there is scheduled for March, although settlement talks continue.

Quick Settlement?

Lawyers for Stamford, Conn.-based Purdue approached some state attorneys general last year hoping to come up with a quick and affordable settlement of lawsuits seeking to recoup the costs of dealing with the fallout from opioid addictions.

But six people familiar with the talks said this month they were stalled over the question of who will pay to provide extra funding for law-enforcement and drug treatment budgets, Bloomberg News reported May 3. The companies want to test their defenses to the state’s claims before discussing a multibillion-dollar settlement, the people said.

Slatery’s and Bondi’s decision to sue is an acknowledgment opioid makers and distributors won’t get serious about settling suits until the cases go to trial, said Mike Papantonio, a Florida-based lawyer involved in the litigation.

“You can’t accomplish anything in terms of getting companies to admit they are responsible without filing lawsuits,” Papantonio said. “There won’t be any closure on this without litigation.”

Leigh Ann Jones, Slatery’s spokeswoman, said Tennessee’s top lawyer “will continue to play a leadership role in the multistate effort and settlement discussions.”

Bondi said she wanted an out-of-court deal even though she’d joined the ranks of states suing opioid makers. “We will never stop negotiating,” she said at a press conference Tuesday. The suit is a warning that Florida officials are “fully prepared to go to war” if the companies balk at a settlement, she added.

George Jepsen, Connecticut’s attorney general and another leader of the multistate talks, said Slatery and Bondi should press ahead with settlement talks. “We anticipate they will continue in their leadership rolls going forward,” he said.

Other attorneys general have dropped out of the talks because they wanted to move aggressively to recover the billions of dollars spent on the opioid crisis. More than 100 Americans die daily from opioid overdoses.

The consolidated case by the cities and counties is In Re: National Prescription Opiate Litigation, 17-md-2804, U.S. District Court, Northern District of Ohio (Cleveland).

About the Author
By Bloomberg
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

HealthDietary Supplements
Seed Probiotic Review (2026): Expert Tested and Approved
By Christina SnyderMarch 26, 2026
2 hours ago
wyle
HealthTV
‘The Pitt’ shows an ER getting shut down by a cyberattack that is totally true to life
By Jeffrey Tully, Christian Dameff and The ConversationMarch 26, 2026
3 hours ago
HealthTech
What is tech addiction? A court ruling makes it Big Tech’s next big problem
By Kristin StollerMarch 26, 2026
9 hours ago
HealthDietary Supplements
The Best Colostrum Supplements 2026: Tested and Approved
By Emily PharesMarch 24, 2026
2 days ago
Personal FinanceTaxes
Americans spend $146 billion and 11.6 billion hours doing their taxes, and most of it is just filling out paperwork
By Catherina GioinoMarch 24, 2026
2 days ago
fauci
CommentaryCOVID-19 vaccines
How COVID turned America against science — and what it will take to win it back
By David Blumenthal and James A. MoroneMarch 24, 2026
2 days ago

Most Popular

Success
Palantir’s billionaire CEO says only two kinds of people will succeed in the AI era: trade workers — ‘or you’re neurodivergent’
By Fortune EditorsMarch 24, 2026
2 days ago
Magazine
The youngest-ever female CEO of a Fortune 500 company is fighting Trump's cuts to keep Medicaid strong
By Fortune EditorsMarch 24, 2026
2 days ago
C-Suite
'I didn’t want anybody shooting me': Five Guys CEO gave away $1.5 million bonus to employees over botched BOGO burger birthday celebration
By Fortune EditorsMarch 25, 2026
21 hours ago
Commentary
The Treasury just declared the U.S. insolvent. The media missed it
By Fortune EditorsMarch 23, 2026
3 days ago
Success
JPMorgan’s Jamie Dimon says remote work breeds ‘rope-a-dope politics’ and stunts young workers’ growth
By Fortune EditorsMarch 25, 2026
1 day ago
Environment
Vail Resorts' CEO says it's time to think beyond the $1,000 ski pass that helped build the empire
By Fortune EditorsMarch 26, 2026
9 hours ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.